Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog

INTRODUCTION: Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment. We aimed to investigate the impact of aspirin on reducing HCC risk in patients treated with first-line oral nucleos(t)ide analogs (NAs; entecavir a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Transl Gastroenterol
Prif Awduron: Hui, Vicki Wing-Ki, Yip, Terry Cheuk-Fung, Wong, Vincent Wai-Sun, Tse, Yee-Kit, Chan, Henry Lik-Yuen, Lui, Grace Chung-Yan, Wong, Grace Lai-Hung
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8126482/
https://ncbi.nlm.nih.gov/pubmed/33750746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/ctg.0000000000000324
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg